Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin

被引:65
|
作者
Kovacs, MJ [1 ]
Keeney, M [1 ]
MacKinnon, K [1 ]
Boyle, E [1 ]
机构
[1] London Hlth Sci Ctr, London, ON, Canada
来源
CLINICAL AND LABORATORY HAEMATOLOGY | 1999年 / 21卷 / 01期
关键词
heparin; dalteparin; monitoring; anti-Xa levels; thrombosis;
D O I
10.1046/j.1365-2257.1999.00183.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this study we compare three chromogenic methods (IL-Heparin, Stachrom Heparin and Heparin Sigma) on two different instruments (ACL300+ and AMAX CS190) for patients on dalteparin (n = 41), a low molecular weight heparin or unfractionated heparin (n = 50). For dalteparin the mean anti-Xa levels for IL-Heparin, Stachrom Heparin and Heparin Sigma were 0.27, 0.30 and 0.21U/ml, respectively, while for heparin they were 0.52, 0.55 and 0.41U/ml, respectively. To test for instrument specific effects, IL-Heparin and Stachrom Heparin were repeated on both instruments on 42 patients receiving unfractionated heparin. For IL-Heparin the mean anti-Xa levels on the AMAX CS190 and ACL300+ were 0.51 and 0.59 U/ml, respectively, while for Stachrom Heparin they were 0.55 and 0.67 anti-Xa U/ml. We conclude that different chromogenic anti-Xa methods do not give equivalent anti-Xa levels for the same samples. Moreover, the differences are clinically significant. This is not explained entirely by instrumentation effects,Recommended therapeutic ranges may need to be method and instrument specific.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 50 条
  • [1] Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic dalteparin or unfractionated heparin.
    Kovacs, MJ
    Keeney, M
    MacKinnon, K
    Boyle, E
    [J]. BLOOD, 1996, 88 (10) : 708 - 708
  • [2] Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin)
    PerezRequejo, JL
    LucenaSolano, O
    PerezGarcia, M
    Santarelli, MT
    [J]. THROMBOSIS RESEARCH, 1997, 85 (03) : 259 - 265
  • [3] Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (Enoxaparin)
    PerezRequejo, JL
    LucenaSolano, O
    PerezGarcia, M
    Santarelli, MT
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : P1172 - P1172
  • [4] Current DVT Prophylaxis Guidelines with Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH) Are Inadequate for MICU Patients by Anti-Xa Levels
    Velasquez, A.
    Patel, H.
    Shaz, D.
    Perez, R. L.
    Leeper, K. V.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [5] INCREASED ANTI-XA BIOAVAILABILITY FOR A LOW-MOLECULAR WEIGHT HEPARIN (PK-10169) COMPARED WITH UNFRACTIONATED HEPARIN
    BARA, L
    BILLAUD, E
    KHER, A
    SAMAMA, M
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1985, 11 (03): : 316 - 317
  • [6] Is monitoring anti-Xa levels necessary in pregnant women on therapeutic low molecular weight heparin (LMWH)?
    Temming, Lorene A.
    Young, Omar M.
    Stout, Molly J.
    Tuuli, Methodius G.
    Macones, George A.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : S157 - S158
  • [7] Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels
    Alex M. Ebied
    Tammy Li
    Samantha F. Axelrod
    Douglas J. Tam
    Yiqing Chen
    [J]. Journal of Thrombosis and Thrombolysis, 2020, 49 : 206 - 213
  • [8] Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels
    Ebied, Alex M.
    Li, Tammy
    Axelrod, Samantha F.
    Tam, Douglas J.
    Chen, Yiqing
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 49 (02) : 206 - 213
  • [9] IMPACT OF DOSE-CAPPING ON TIME TO THERAPEUTIC ANTI-XA LEVELS FOR WEIGHT-BASED UNFRACTIONATED HEPARIN
    LaBianca, Rachel
    Barakat, Oksana
    Green, Jane
    Liang, Debbie
    Peak, Jared
    Hamblin, Susan
    Collins, David
    [J]. CRITICAL CARE MEDICINE, 2018, 46 (01) : 58 - 58
  • [10] ANTI-XA POTENTIATING EFFECT OF LOW-MOLECULAR WEIGHT HEPARIN
    JUNKER, W
    HARENBERG, J
    FUSSI, F
    MATTES, K
    ZIMMERMANN, R
    WEBER, E
    [J]. THROMBOSIS AND HAEMOSTASIS, 1981, 46 (01) : 235 - 235